Adria Cimino

Adria Cimino


Adria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg News in Paris. When she’s not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter.

Recent articles

Is Gilead Sciences Stock a Buy?

Gilead Sciences has drawn attention to itself with a possible coronavirus treatment -- but that isn’t the main reason to invest in the company.

Is Seattle Genetics Stock a Buy?

With a new drug on the market and another being reviewed by the FDA, Seattle Genetics’ revenue potential is climbing.

How Risky Is L Brands?

Share volatility and rumors of a Victoria’s Secret sale stir up uncertainty for investors.

Is Boston Scientific Stock a Buy?

Boston Scientific’s recent earnings report was mixed, but FDA clearance of a potentially blockbuster device could drive future revenue -- and stock performance. Buy at the High?

How many times have you asked yourself how shares can possibly move higher? Steady revenue and profit growth, as well as diversification, may be why it’s rarely too late to buy into the Amazon story.

Is Amgen a Stock to Buy?

Amgen’s pipeline and an oncology collaboration in China are reasons to believe the recent revenue slowdown may be transient.

Is Illumina Stock a Buy?

Illumina’s share of the sequencing market, new collaboration agreement with Roche, and growth in the clinical oncology business position it for long-term revenue growth.